The Glutamatergic Dysfunction Hypothesis for Schizophrenia

&NA; Schizophrenia is a syndrome, undoubtedly with multiple etiologies, that variably exhibits several features including positive and negative symptoms, cognitive deficits, onset in young adulthood, and deterioration from the previous level of function. This review will examine the growing evidence that dysfunction of corticolimbic glutamatergic neurotransmission may contribute to or account for the manifestations of schizophrenia. Glutamatergic neurons represent the primary excitatory afferent and efferent systems innervating the cortex, limbic regions, and striatum. The postsynaptic actions of glutamate are mediated by a family of glutamate‐gated ion channels that permit the influx of sodium and calcium, thereby depolarizing (exciting) neurons. One of these receptors, the W‐methyl‐D‐aspartate (NMDA) receptor, is the site of action of psychotomimetics such as phencyclidine and related anesthetics, which can reproduce in normal individuals most of the symptomatic features of schizophrenia. An endogenous antagonist at the NMDA receptor, W‐acetyl‐aspartyl glutamate, appears to have enhanced activity in the frontal cortex and hippo‐campal formation in persons with this disorder. Glutamatergic dysfunction may be particularly relevant to those forms of schizophrenia in which negative symptoms, cognitive deficits, and deterioration are prominent features. In support of this inference, clinical studies have shown that drugs that enhance NMDA‐receptor function reduce negative symptoms and cognitive deficits in persons with chronic schizophrenia who are receiving neuroleptics. Thus, dysfunction of glutamatergic neurotransmission represents an important organizational focus for research on the complex manifestations of schizophrenia.

[1]  P. Renshaw,et al.  Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls , 1996, Schizophrenia Research.

[2]  Dyskinesia. Research and treatment. , 1985, Psychopharmacology. Supplementum.

[3]  J. O'Callaghan Biochemical analysis of glial fibrillary acidic protein as a quantitative approach to neurotoxicity assessment: advantages, disadvantages and application to the assessment of NMDA receptor antagonist-induced neurotoxicity. , 1994, Psychopharmacology bulletin.

[4]  J. Olney,et al.  Glutamatergic, Cholinergic, and GABAergic Systems in Posterior Cingulate Cortex: Interactions and Possible Mechanisms of Limbic System Disease , 1993 .

[5]  B. Zeeberg,et al.  Elevated D2 dopamine receptors in drug-naïve schizophrenics. , 1988, Science.

[6]  J. Coyle,et al.  Kainic acid induces apoptosis in neurons , 1996, Neuroscience.

[7]  J. Olney,et al.  Excitotoxic amino acids and neuropsychiatric disorders. , 1990, Annual review of pharmacology and toxicology.

[8]  A. Deutch,et al.  Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[9]  B. Moghaddam,et al.  Stress Preferentially Increases Extraneuronal Levels of Excitatory Amino Acids in the Prefrontal Cortex: Comparison to Hippocampus and Basal Ganglia , 1993, Journal of neurochemistry.

[10]  J. Coyle,et al.  Excitatory amino acid analogues: Neurotoxicity and seizures , 1982, Neuropharmacology.

[11]  P. Slater,et al.  Frontal Cortical and Left Temporal Glutamatergic Dysfunction in Schizophrenia , 1989, Journal of neurochemistry.

[12]  A Carlsson,et al.  Antipsychotic drugs, neurotransmitters, and schizophrenia. , 1978, The American journal of psychiatry.

[13]  A. Davies,et al.  The proto-oncogene bcl-2 can selectively rescue neurotrophic factor-dependent neurons from apoptosis , 1993, Cell.

[14]  J. Coyle,et al.  The neurobiology of N-acetylaspartylglutamate. , 1988, International review of neurobiology.

[15]  T. O'donohue,et al.  Glycine modulation of the phencyclidine binding site in mammalian brain , 1988, Brain Research.

[16]  T. Bliss,et al.  Long‐lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path , 1973, The Journal of physiology.

[17]  A Carlsson,et al.  Schizophrenia: a subcortical neurotransmitter imbalance syndrome? , 1990, Schizophrenia bulletin.

[18]  J. Kane,et al.  Tardive dyskinesia: prevalence and risk factors, 1959 to 1979 , 1982, Archives of general psychiatry.

[19]  K. Jellinger,et al.  DOPAMINE RECEPTORS AND SCHIZOPHRENIA: DRUG EFFECT OR ILLNESS , 1980, The Lancet.

[20]  R. Gur,et al.  Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. , 1994, Archives of general psychiatry.

[21]  G. Chouinard,et al.  A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. , 1988, Journal of clinical psychopharmacology.

[22]  John Calvin Reed Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.

[23]  P. Wood,et al.  Actions of d-cycloserine at the N-methyl-d-aspartate-associated glycine receptor site in vivo , 1991, Neuropharmacology.

[24]  N. Mataga,et al.  Neurotransmitters, receptors and neuropeptides in post‐mortem brains of chronic schizophrenic patients , 1988, Acta psychiatrica Scandinavica.

[25]  J. L. Stringer,et al.  Blockade of long-term potentiation by phencyclidine and σ opiates in the hippocampus in vivo and in vitro , 1983, Brain Research.

[26]  T. Nishikawa,et al.  Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia , 1983, Neuroscience Letters.

[27]  J. Coyle,et al.  Immunocytochemical distribution of n-acetylaspartylglutamate in the rat forebrain and glutamatergic pathways , 1993, Journal of Chemical Neuroanatomy.

[28]  G. Pearlson,et al.  Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. , 1986, Science.

[29]  M. Egan,et al.  Treatment of tardive dyskinesia with vitamin E. , 1992, The American journal of psychiatry.

[30]  F. Benes,et al.  Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. , 1986, Archives of general psychiatry.

[31]  M. Bolanowski,et al.  d-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed inXenopus oocytes , 1990, Brain Research.

[32]  James K. T. Wang,et al.  Presynaptic Glutamate Receptors Modulate Dopamine Release from Striatal Synaptosomes , 1991, Journal of neurochemistry.

[33]  J. Rothstein,et al.  Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[34]  W. Greenough,et al.  Differential rearing effects on rat visual cortex synapses. III. Neuronal and glial nuclei, boutons, dendrites, and capillaries , 1987, Brain Research.

[35]  S. Matthysse Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? , 1973, Federation proceedings.

[36]  J. Coyle,et al.  Selective release ofN-acetylaspartylglutamate from rat optic nerve terminals in vivo , 1990, Brain Research.

[37]  M. LeMay,et al.  Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. , 1992, The New England journal of medicine.

[38]  S. Nakanishi Molecular diversity of glutamate receptors and implications for brain function. , 1992, Science.

[39]  E. Walker,et al.  Sampling biases in studies of gender and schizophrenia. , 1993, Schizophrenia bulletin.

[40]  J. Coyle,et al.  N-Acetylaspartate in neuropsychiatric disorders , 1995, Progress in Neurobiology.

[41]  W. Löscher,et al.  Effect of the glycine/NMDA receptor partial agonist, D-cycloserine, on seizure threshold and some pharmacodynamic effects of MK-801 in mice. , 1994, European journal of pharmacology.

[42]  J. Coyle,et al.  Immunocytochemical localization of the N‐acetyl‐aspartyl‐glutamate (NAAG) hydrolyzing enzyme N‐acetylated α‐linked acidic dipeptidase (NAALADase) , 1992, The Journal of comparative neurology.

[43]  N. Andreasen,et al.  A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. , 1995, Archives of general psychiatry.

[44]  F. Benes,et al.  Myelination of cortical-hippocampal relays during late adolescence. , 1989, Schizophrenia bulletin.

[45]  Z. Oltvai,et al.  Bcl-2 functions in an antioxidant pathway to prevent apoptosis , 1993, Cell.

[46]  J. Lieberman,et al.  Duration of psychosis and outcome in first-episode schizophrenia. , 1992, The American journal of psychiatry.

[47]  K. Okamoto,et al.  Low-concentration N-acetylaspartylglutamate suppresses the climbing fiber response of Purkinje cells in Guinea pig cerebellar slices and the responses to excitatory amino acids of Xenopus laevis oocytes injected with cerebellar mRNA , 1989, Brain Research.

[48]  B. Moghaddam,et al.  Glutamatergic Control of Dopamine Release During Stress in the Rat Prefrontal Cortex , 1994, Journal of neurochemistry.

[49]  Youssef Ha,et al.  An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms. , 1986 .

[50]  D. Casey,et al.  Computed tomographic evaluation of patients with tardive dyskinesia , 1991, Schizophrenia Research.

[51]  J. Peto,et al.  Molecular pathology of schizophrenia: more than one disease process? , 1980 .

[52]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1976 .

[53]  J. Olney,et al.  Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. , 1994, The Journal of clinical psychiatry.

[54]  S. Snyder,et al.  Dopamine receptors localised on cerebral cortical afferents to rat corpus striatum , 1978, Nature.

[55]  B. Bogerts,et al.  Limbic pathology in schizophrenia: The entorhinal region—a morphometric study , 1988, Biological Psychiatry.

[56]  A. Starr,et al.  Latency variability of the components of auditory event-related potentials to infrequent stimuli in aging, Alzheimer-type dementia, and depression. , 1988, Electroencephalography and clinical neurophysiology.

[57]  K O Lim,et al.  Widespread cerebral gray matter volume deficits in schizophrenia. , 1992, Archives of general psychiatry.

[58]  J. Coyle,et al.  Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies , 1991, Neuroscience.

[59]  D. Pickar,et al.  National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. , 1991, Archives of general psychiatry.

[60]  Announcementssion tomography reveals elevated D2, dopamine receptors in drug-naive schizophrenics , 1994, Psychiatry Research: Neuroimaging.

[61]  P. Francis,et al.  d-Cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-d-aspartate receptor-ionophore complex in Alzheimer brain , 1991, Brain Research.

[62]  Brian A. Lawlor,et al.  Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? , 1992, Biological Psychiatry.

[63]  J. Neale,et al.  N‐Acetylaspartylglutamate Inhibits Forskolin‐Stimulated Cyclic AMP Levels via a Metabotropic Glutamate Receptor in Cultured Cerebellar Granule Cells , 1993, Journal of neurochemistry.

[64]  L. Noble,et al.  MK‐801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex , 1991, Annals of neurology.

[65]  N CORBOUD,et al.  [The general anesthetics]. , 1952, Schweizerische Monatsschrift fur Zahnheilkunde = Revue mensuelle suisse d'odonto-stomatologie.

[66]  G. Collingridge,et al.  Excitatory amino acids in synaptic transmission in the Schaffer collateral‐commissural pathway of the rat hippocampus. , 1983, The Journal of physiology.

[67]  S H Snyder,et al.  Drugs, neurotransmitters, and schizophrenia. , 1974, Science.

[68]  G. Reynolds,et al.  ASYMMETRICAL LOSS OF GLUTAMATE RECEPTOR SUBTYPE IN LEFT HIPPOCAMPUS IN SCHIZOPHRENIA , 1988, The Lancet.

[69]  S. Heinemann,et al.  Cloned glutamate receptors. , 1994, Annual review of neuroscience.

[70]  J. Waddington,et al.  An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms. , 1986, The American journal of psychiatry.

[71]  J. Coyle,et al.  Glutamate and related acidic excitatory neurotransmitters: from basic science to clinical application , 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[72]  E. G. Jones,et al.  Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. , 1995, Archives of general psychiatry.

[73]  L. Iversen,et al.  Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia. , 1979, Brain : a journal of neurology.

[74]  A. Kriegstein,et al.  Glutamate neurotoxicity in cortical cell culture , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[75]  T. Hicks,et al.  Excitatory amino acid transmission , 1987 .

[76]  S. Anand,et al.  Phencyclidine poisoning in young children. , 1980, The Journal of pediatrics.

[77]  H. Fibiger,et al.  D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons , 1992, Neuroscience.

[78]  T. White,et al.  The association among negative symptoms, movement disorders, and frontal lobe psychological deficits in schizophrenic patients , 1991, Biological Psychiatry.

[79]  J. Olney GLUTAMATE‐INDUCED NEURONAL NECROSIS IN THE INFANT MOUSE HYPOTHALAMUS: An Electron Microscopic Study , 1971, Journal of neuropathology and experimental neurology.

[80]  P. Conn,et al.  Metabotropic glutamate receptors in brain function and pathology. , 1993, Trends in pharmacological sciences.

[81]  E. Levin,et al.  Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia , 1989, Movement disorders : official journal of the Movement Disorder Society.

[82]  M. Alexander,et al.  Principles of Neural Science , 1981 .

[83]  J. Ehrhardt,et al.  Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. , 1994, Science.

[84]  J. Olney,et al.  Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. , 1989, Science.

[85]  J. Desce,et al.  Glutamatergic Control of Dopamine Release in the Rat Striatum: Evidence for Presynaptic N‐Methyl‐D‐Aspartate Receptors on Dopaminergic Nerve Terminals , 1991, Journal of neurochemistry.

[86]  J. Coyle,et al.  Oxidative stress, glutamate, and neurodegenerative disorders. , 1993, Science.

[87]  M. Robinson,et al.  Kindling increases brain levels of NAAG and seizures reduce activity of a NAAG-hydrolyzing enzyme, NAALADase. , 1992, Epilepsy research. Supplement.

[88]  J. Coyle,et al.  Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. , 1987, The Journal of biological chemistry.

[89]  H. Wright,et al.  Phencyclidine-induced psychosis. , 1980, Southern medical journal.

[90]  G Maura,et al.  Release-regulating D-2 dopamine receptors are located on striatal glutamatergic nerve terminals. , 1988, The Journal of pharmacology and experimental therapeutics.

[91]  R. Kerwin,et al.  Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem , 1990, Neuroscience.

[92]  C. Tanaka,et al.  [3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics. , 1987, Life sciences.

[93]  G. Lynch,et al.  Synapses, circuits, and the beginnings of memory , 1986 .

[94]  D. Weinberger,et al.  Structural abnormalities in the cerebral cortex of chronic schizophrenic patients. , 1979, Archives of general psychiatry.

[95]  B. Carroll,et al.  Psychopathology and the brain , 1991 .

[96]  David Krech,et al.  Increases in cortical depth and glia numbers in rats subjected to enriched environment , 1966, The Journal of comparative neurology.

[97]  B. Barres,et al.  Programmed cell death and the control of cell survival: lessons from the nervous system. , 1993, Science.

[98]  Sohee Park,et al.  Schizophrenics show spatial working memory deficits. , 1992, Archives of general psychiatry.

[99]  J. Kleinman,et al.  Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. , 1995, Archives of general psychiatry.

[100]  M. Hennerici,et al.  Event-related potentials in patients with Huntington's disease and relatives at risk in relation to detailed psychometry. , 1986, Electroencephalography and clinical neurophysiology.

[101]  A. Wyllie,et al.  Cell death: the significance of apoptosis. , 1980, International review of cytology.

[102]  E. Roberts Prospects for research on schizophrenia. An hypotheses suggesting that there is a defect in the GABA system in schizophrenia. , 1972, Neurosciences Research Program bulletin.

[103]  J. Collinge,et al.  Decreased Hippocampal Expression of a Glutamate Receptor Gene in Schizophrenia , 1991, British Journal of Psychiatry.

[104]  L. Gunne,et al.  Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis , 1984, Nature.

[105]  L. Noble,et al.  Haloperidol prevents induction of the hsp70 heat shock gene in neurons injured by phencyclidine (PCP), MK801, and ketamine , 1992, Journal of neuroscience research.

[106]  E. Bird,et al.  Organization of dopamine D1 and D2 receptors in human striatum: Receptor autoradiographic studies in Huntington's disease and schizophrenia , 1988, Synapse.

[107]  J. Coyle,et al.  Quantitation of N-acetyl-aspartyl-glutamate in microdissected rat brain nuclei and peripheral tissues: findings with a novel liquid phase radioimmunoassay. , 1988, Brain research.

[108]  F. Bloom,et al.  Advancing a neurodevelopmental origin for schizophrenia. , 1993, Archives of general psychiatry.

[109]  R. Kikinis,et al.  Increased rate of P300 latency prolongation with age in schizophrenia. Electrophysiological evidence for a neurodegenerative process. , 1995, Archives of general psychiatry.

[110]  B. Pakkenberg,et al.  Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. , 1990, Archives of general psychiatry.

[111]  J. Coyle,et al.  Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. , 1995, The American journal of psychiatry.

[112]  R. Tandon,et al.  Negative symptoms of schizophrenia: The need for conceptual clarity , 1991, Biological Psychiatry.

[113]  J. Olney,et al.  Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity , 1993, Biological Psychiatry.

[114]  T. V. Nguyen,et al.  The cAMP-response-element-binding protein interacts, but Fos protein does not interact, with the proenkephalin enhancer in rat striatum. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[115]  D. Jeste,et al.  Hippocampal pathologic findings in schizophrenia. A morphometric study. , 1989, Archives of general psychiatry.

[116]  H. Nasrallah,et al.  Contemporary Issues in the Treatment of Schizophrenia , 1995 .

[117]  K. Kendler,et al.  The genetics of schizophrenia: a current, genetic-epidemiologic perspective. , 1993, Schizophrenia bulletin.

[118]  H. Meltzer,et al.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.

[119]  O'Callaghan Jp Biochemical analysis of glial fibrillary acidic protein as a quantitative approach to neurotoxicity assessment: advantages, disadvantages and application to the assessment of NMDA receptor antagonist-induced neurotoxicity. , 1994 .

[120]  M. Dragunow,et al.  D2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons , 1990, Neuroscience.

[121]  G. Fein,et al.  Reduced brain N‐acetylaspartate suggests neuronal loss in cognitively impaired human immunodeficiency virus‐seropositive individuals , 1993, Neurology.

[122]  G. Cohen,et al.  Schizophrenia and aging : schizophrenia, paranoia, and schizophreniform disorders in later life , 1987 .

[123]  S. Heckers,et al.  Hippocampal neuron number in schizophrenia. A stereological study. , 1991, Archives of general psychiatry.

[124]  M. Gabriel,et al.  Neurobiology of Cingulate Cortex and Limbic Thalamus , 1993 .

[125]  J. Coyle,et al.  Kainic acid-induced lipid peroxidation: protection with butylated hydroxytoluene and U78517F in primary cultures of cerebellar granule cells , 1993, Brain Research.

[126]  W. Pollin Heredity and Environment in Schizophrenia, Revisited: The Contribution of Twin and High-Risk Studies , 1993, The Journal of nervous and mental disease.

[127]  G. Rosenbaum,et al.  Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium; II. Symbolic and sequential thinking. , 1962, Archives of general psychiatry.

[128]  M. Fabri,et al.  Glutamate-positive corticocortical neurons in the somatic sensory areas I and II of cats , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[129]  H. Fibiger,et al.  Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. , 1994, The Journal of pharmacology and experimental therapeutics.

[130]  J. Coyle,et al.  Rat brain N-acetylated alpha-linked acidic dipeptidase activity. Purification and immunologic characterization. , 1990, The Journal of biological chemistry.

[131]  F. Benes,et al.  Reduced neuronal size in posterior hippocampus of schizophrenic patients. , 1991, Schizophrenia bulletin.

[132]  R. Heaton,et al.  Clinical neuropsychological findings in schizophrenia and aging. , 1987 .

[133]  C A Sandman,et al.  Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. , 1993, Archives of general psychiatry.

[134]  F. Benes Is There a Neuroanatomic Basis for Schizophrenia? An Old Question Revisited , 1995 .

[135]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[136]  A. Cooper,et al.  Glutamate-induced apoptosis results in a loss of striatal neurons in the parkinsonian rat , 1994, Neuroscience.

[137]  H. Iwainsky Mode of Action, Biotransformation and Pharmacokinetics of Antituberculosis Drugs in Animals and Man , 1988 .

[138]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[139]  F. Bloom Principles of Neural Science, 3rd ed , 1993 .

[140]  P. Ascher,et al.  Competitive antagonists and partial agonists at the glycine modulatory site of the mouse N‐methyl‐D‐aspartate receptor. , 1990, The Journal of physiology.

[141]  D. Javitt,et al.  Amelioration of negative symptoms in schizophrenia by glycine. , 1994, The American journal of psychiatry.

[142]  G D Pearlson,et al.  Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. , 1990, The American journal of psychiatry.

[143]  R. Buchanan,et al.  Strong inference, theory testing, and the neuroanatomy of schizophrenia. , 1993, Archives of general psychiatry.

[144]  L. Kerkérian,et al.  Modulatory Effect of Dopamine on High‐Affinity Glutamate Uptake in the Rat Striatum , 1987, Journal of neurochemistry.

[145]  J. Kleinman,et al.  Cerebral ventricular enlargement in chronic schizophrenia. An association with poor response to treatment. , 1980, Archives of general psychiatry.